Patents by Inventor David Francis Alain Lancois

David Francis Alain Lancois has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaromatic compounds having activity against RSV
    Patent number: 11708369
    Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: July 25, 2023
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérome Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Peter Rigaux, Antoine Benjamin Michaut, Sabrina Dany France Quatrevaux, Sovy Chao, Dirk André Emmy Roymans
  • Cycloalkyl substituted pyrazolopyrimidines having activity against RSV
    Patent number: 11491157
    Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. (Formula I).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: November 8, 2022
    Assignee: Janssen Sciences Ireland Unlimited Company Co Cork, IE
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Peter Rigaux, Antoine Benjamin Michaut
  • Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV)
    Patent number: 11339165
    Abstract: The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 24, 2022
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Peter Rigaux, Antoine Benjamin Michaut, Guillaume Jean Maurice Mercey
  • FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV
    Publication number: 20220033396
    Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial vims (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment or prevention of respiratory syncytial vims infection.
    Type: Application
    Filed: November 25, 2019
    Publication date: February 3, 2022
    Inventors: Jérome Émile Georges GUILLEMONT, David Francis Alain LANÇOIS, Sovy CHAO, Patrick René ANGIBAUD, Guillaume Jean Maurice MERCEY, Pierre Jean-Marie Bernard RABOISSON, Antoine Benjamin MICHAUT, Peter RIGAUX
  • RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
    Patent number: 11084826
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: August 10, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
  • HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV
    Publication number: 20210094958
    Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: April 19, 2019
    Publication date: April 1, 2021
    Inventors: David Francis Alain LANÇOIS, Jérome Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Peter RIGAUX, Antoine Benjamin MICHAUT, Sabrina Dany France QUATREVAUX, Sovy CHAO, Dirk André Emmy ROYMANS
  • PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV)
    Publication number: 20200361942
    Abstract: The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).
    Type: Application
    Filed: November 28, 2017
    Publication date: November 19, 2020
    Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Peter RIGAUX, Antoine Benjamin MICHAUT, Guillaume Jean Maurice MERCEY
  • CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV
    Publication number: 20200360387
    Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: January 30, 2019
    Publication date: November 19, 2020
    Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Peter RIGAUX, Antoine Benjamin MICHAUT
  • RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS
    Publication number: 20200223855
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: March 30, 2020
    Publication date: July 16, 2020
    Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Boris ROGOVOY, Vadim BICHKO, Delphine Yvonne Raymonde LARDEAU, Antoine Benjamin MICHAUT, Anil KOUL
  • RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
    Patent number: 10611769
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: April 7, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
  • Functionalized pentanoic acids for use influenza viral infections
    Patent number: 10526338
    Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: January 7, 2020
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Wendy Mia Albert Balemans, David Craig McGowan, Magali Madeleine Simone Motte, David Francis Alain Lançois, Emilie Marie Lambert
  • Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Patent number: 10526331
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 7, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Patent number: 10501463
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: December 10, 2019
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS
    Publication number: 20190248793
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 15, 2019
    Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Boris ROGOVOY, Vadim BICHKO, Delphine Yvonne Raymonde LARDEAU, Antoine Benjamin MICHAUT, Anil KOUL
  • ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES
    Publication number: 20190194194
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 27, 2019
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES
    Publication number: 20190084982
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Application
    Filed: November 16, 2018
    Publication date: March 21, 2019
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
    Patent number: 10208048
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: February 19, 2019
    Assignee: Janssen Sciences Ireland UC
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
  • FUNCTIONALIZED PENTANOIC ACIDS FOR USE INFLUENZA VIRAL INFECTIONS
    Publication number: 20190023713
    Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
    Type: Application
    Filed: January 5, 2017
    Publication date: January 24, 2019
    Inventors: Jérôme Émile Georges GUILLEMONT, Wendy Mia Albert BALEMANS, David Craig MC GOWAN, Magali Madeleine Simone MOTTE, David Francis Alain LANÇOIS, Emilie Marie LAMBERT
  • Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Patent number: 10155759
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 18, 2018
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • Substituted pyridine-piperazinyl analogues as RSV antiviral compounds
    Patent number: 10150761
    Abstract: The invention concerns novel substituted pyridine-piperazinyl analogs of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: December 11, 2018
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Delphine Yvonne Raymonde Lardeau, Xavier Marc Bourdrez, Wendy Mia Albert Balemans, Dirk André Emmy Roymans